Induction of tumors of the liver, lung ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: Promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers

Carcinogenesis

Volumn 25, Issue 1, 2004, Pages 133-141

  Waalkes, Michael P ^a   Ward, Jerrold M ^b   Diwan, Bhalchandra A ^c  

^a National Cancer Institute   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENITE SODIUM; CARCINOGEN; DRINKING WATER; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER;

ADRENAL TUMOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; HYPERPLASIA; LETHAL DOSE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG CARCINOGENESIS; LUNG TUMOR; MALE; MOUSE; NONHUMAN; OVARY TUMOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; SKIN TUMOR; TISSUE SPECIFICITY; TRANSPLACENTAL CARCINOGENESIS;

ADRENAL GLAND NEOPLASMS; ANIMALS; ARSENIC; FEMALE; FETUS; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C3H; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 1642545601     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgg181     Document Type: Article

References (49)

1. IARC (1987) International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans: Supplement 7, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs. IARC Scientific Publications, IARC Lyon, Vol. 1-42, pp. 100-106.
2. NRC (1999) National Research Council: Arsenic in the Drinking Water. National Academy Press, Washington, DC, pp. 1-310.
3. Smith,A.H., Hopenhayn-Rich,C., Bates,M.N., Goeden,H.M., Hertz-Picciotto,I., Duggan,H.M., Wood,R., Kosnett,M.J. and Smith,M.T. (1992) Cancer risks from arsenic in drinking water. Environ. Health Perspect., 97, 259-267.
4. Bates,M.N., Smith,A.H. and Hopenhayn-Rich,C. (1992) Arsenic ingestion and internal cancers: a review. Am. J. Epidemiol., 135, 462-476.
5. Simeonova,P.P. and Luster,M.I. (2000) Mechanisms of arsenic carcinogencity: genetic or epigenetic mechanisms? J. Environ. Pathol. Oncol., 19, 281-286.
6. Kitchin,K.T. (2001) Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol., 172, 249-261.
7. Pott,W.A., Benjamin,S.A. and Yang,R.S.H. (2001) Pharmacokinetics, metabolism and carcinogenicity of arsenic. Rev. Environ. Contam. Toxicol., 169, 165-214.
8. Lewis,D.R., Southwick,J.W., Ouellet-Hellstrom,R., Rench,J. and Calderon,R.L. (1999) Drinking water arsenic in Utah: a cohort mortality study. Environ. Health Perspect., 107, 359-365.
9. Morales,K.H., Ryan,L., Kuo,T.-L., Wu,M.-M. and Chen,C.-J. (2000) Risk of internal cancers from arsenic in the drinking water. Environ. Health Perspect., 108, 655-661.
10. Zhao,C.Q., Young,M.R., Diwan,B.A., Coogan,T.P. and Waalkes,M.P. (1997) Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl Acad. Sci. USA, 94, 10907-10912.
11. Germolec,D.R., Spalding,J., Boorman,G.A. et al. (1997) Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat. Res., 386, 209-218.
12. Germolec,D.R., Spalding,J., Yu,H.-S. et al. (1998) Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol., 153, 1775-1785.
13. Rossman,T.G., Uddin,A.N., Burns,F.J. and Bosland,M.C. (2001) Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol., 176, 64-71.
14. Anderson, L.M., Diwan,B.A., Rear,N.T. and Roman,E. (2000) Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasma in experimental animal models. Environ. Health Perspect., 108 (suppl.3), 573-594.
15. 1 mice exposed to lead acetate during gestation and lactation occur with minimal chronic nephropathy. Cancer Res., 55, 5265-5271.
16. Diwan,B.A., Kasprzak,K.S. and Rice,J.M. (1992) Transplacental carcinogenic effects of nickel(II) in the renal cortex, renal pelvis and adenohypophysis in F344/NCr. Carcinogenesis, 13, 1351-1357.
17. Diwan,B.A., Anderson,L.M., Rehm,S. and Rice,J.M. (1993) Transplacental carcinogenicity of cisplatin: Initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice. Cancer Res., 53, 3874-3876.
18. Diwan,B.A., Anderson,L.M., Ward,J.M., Henneman,J.R. and Rice,J.M. (1995) Transplacental carcinogenesis by cisplatin in F344/NCr: promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol. Appl. Pharmacol., 132, 115-121.
19. Waalkes,M.P., Diwan,B.A., Liu,J. and Ward,J.M. (2003) Transplacental carcinogenicity of inorganic arsenic in the drinking water: Induction of hepatic, ovarian, pulmonary and adrenal tumors in mice. Toxicol. Appl. Pharmacol., 186, 7-17.
20. Wu,M.-M., Kuo,T.-L., Hwang,Y.-H., and Chen,C.-J. (1989) Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am. J. Epidemiol., 130, 1123-1132.
21. Chen,C.-J. and Wang,C.-J. (1990) Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res., 50, 5470-5474.
22. Waalkes,M.P., Keefer,L.K. and Diwan,B.A. (2000) Induction of proliferative lesions of the uterus, testes, and liver in Swiss mice given repeated injections of sodium arsenate; possible estrogenic mode of action. Toxicol. Appl. Pharmacol., 166, 24-35.
23. Concha,G., Vogler,G., Lezcano,D., Nermell,B. and Vahter,M. (1998) Exposure to inorganic arsenic metabolites during early human development. Toxicol. Sci., 44, 185-190.
24. Lindgren,A., Danielsson,R.G., Dencker,L. and Vathter,M. (1984) Embryotoxicity of arsenite and arsenate: distribution in pregnant mice and monkeys and effects on embryonic cells in vitro. Acta Pharmacol. Toxicol., 54, 311-320.
25. Basu,A., Mahata,J., Gupta,S. and Giri,A.K. (2001) Genetic toxicology of a paradoxical human carcinogen, arsenic: a review. Mutat. Res., 448, 171-194.
26. Angel,J.M., and DiGovanni,J. (1999) Genetics of skin tumor promotion. Prog. Exp. Tumor Res., 35, 143-157.
27. Chen,Y., Megosh,L.C., Gilmour,S.K., Sawicki,J.A. and O'Brien,T.G. (2000) K6/ODC trabsgenic mice as a sensitive model for carcinogen identification. Toxicol. Lett., 116, 27-35.
28. Aposhian,H.V. (1997) Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol., 37, 397-419.
29. Thomas,D.J., Styblo,M. and Lin,S. (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol., 176, 127-144.
30. Styblo,M., Drobna,Z., Jaspers,I., Lin,S. and Thomas,D.J. (2002) The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect., 110 (suppl. 5), 767-771.
31. Yamamoto,S., Konishi,Y., Matsuda,T., Murai,T., Shibata,M.-A., Matsui-Yuasa,I., Otani,S., Kuroda,K., Endo,G. and Fukushima,S. (1995) Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res., 55, 1271-1276.
32. Wei,M., Wanibuchi,H., Salim,E.I., Yamamoto,S., Yoshida,K., Endo,G. and Fukushima,S. (1998) Promotion of NCI-Black-Reiter male rat bladder carcinogenesis by dimethylarsinic acid an organic arsenic compound. Cancer Lett., 134, 29-36.
33. Wei,M., Wanibuchi,H., Yamamoto,S., Li,W. and Fukushima,S. (1999) Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis, 20, 1873-1876.
34. Yamanaka,K., Katsumata,K., Ikuma,K., Hasegawa,A., Nakano,M. and Okada,S. (2000) The role of orally administered dimethylarsinic acid, a main metabolite of inorganic arsenics, in the promotion and progression of UVB-induced skin tumorigenesis in hairless mice. Cancer Lett., 152, 79-85.
35. Wei,M., Wanibuchi,H., Morimura,K., Iwai,S., Yoshida,K. Endo,G., Nakae,D. and Fukushima,S. (2002) Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis, 23, 1387-1397.
36. Yamanaka,K., Mizol,M., Kato,K., Hasegawa,A., Nakano,M. and Okada,S. (2001) Oral administration of dimethylarsinic acid, a main metabolite of inorganic arsenic, in mice promotes skin tumorigenesis initiated by dimethylbenz(a)anthracene with or without ultraviolet B as a promoter. Biol. Pharm. Bull., 24, 510-514.
37. Morikawa,T., Wanibuchi,H., Morimura,K., Ogawa,M. and Fukushima,S. (2000) Promotion of skin carcinogenesis by dimethylarsinic acid in Keratin (K6)/ODC transgenic mice. Jpn. J. Cancer Res., 91, 579-581.
38. Salim,E.I., Wanibuchi,H., Morimura,K., Wei,M., Mitsuhashi,M., Yoshida,K., Endo,G. and Fukushima,S. (2003) Carcinogenicity of dimethylarsinic acid in p53 heterozygous knockout and wild-type C57BL/6 J mice. Carcinogenesis, 24, 335-342.
39. Mass,M.J., Tennant,A., Roop,B.C., Cullen,W.R., Styblo,M., Thomas,D.J. and Kligerman,A.D. (2001) Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol., 14, 355-361.
40. Kenyon,E. and Hughes,M.F. (2001) A concise review of the toxicity and carcinogenicity of dimethylarsinic acid. Toxicology, 160, 227-236.
41. Vega,L., Styblo,M., Patterson,R., Cullen,W., Wang,C. and Germolec,D. (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Phramacol., 172, 225-232.
42. Achanzar,W.E., Brambila,E.M., Diwan,B.A., Webber,M.M. and Waalkes,M.P. (2002) Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl Cancer Inst., 94, 1888-1891.
43. Hughes,M.F., Kenyon,E.M., Edwards,B.C., Mitchell,C.T. and Thomas,D.J. (1999) Strain-dependent disposition of inorganic arsenic in the mouse. Toxicology, 137, 95-108.
44. Armuth,V. and Berenblum,I. (1972) Systemic promoting action of phorbol in liver and lung carcinogenesis in AKR mice. Cancer Res., 32, 2259-2262.
45. Goerttler,K. and Löhrke,H. (1977) Diaplacental carcinogenesis: tumor localization and tumor incidence in NMRI mice after diaplacental initiation with DMBA and urethane and postnatal promotion with phorbol ester TPA in a modified 2-stage Berenblum/Mottram experiment. Virchows Arch. A Path. Anat. Histol., 376, 117-132.
46. Goerttler,K., and Loehrke,H., Hesse,B. and Milz,A. (1981) Diaplacental initiation of NMRI mice with 7,12-dimethylbenz[a]anthracene during gestation during gestation days 6-20 and postnatal treatment of the F1-generation with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate: Tumor incidence in organs other than skin. Carcinogenesis, 2, 1087-1094.
47. Armuth,V. and Berenblum,I. (1977) Possible two-stage transplacental liver carcinogenesis in C57BL/6 mice. Int. J. Cancer, 20, 292-295.
48. Centeno,J.A., Mullick,F.G., Martinez,L., Page,N.P., Gibb,H., Longfellow,D., Thompson,C. and Ladich,E.R. (2002) Pathology related to chronic arsenic exposure. Environ. Health Perspect., 110 (suppl. 5), 883-886.
49. Chen,C.J., Yu,M.W. and Liaw,Y.F. (1997) Epidemiological characteristics and risk factors of hepatocellular carcinoma. J. Gasteroenterol. Hepatol., 12, S294-S308.